Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
about
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate diseaseA simple computer program for calculating PSA recurrence in prostate cancer patientsEmerging PSA-based tests to improve screeningKallikreins as biomarkers for prostate cancerClinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer.Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges.Positive resection margins may not reflect the true margin in patients undergoing radical prostatectomySurgery for high-risk localized prostate cancer.Management of recurrent disease after radical prostatectomy.Prospective investigation of change in the prostate-specific antigens after various urologic procedures.Prostate-specific antigen in serum of women with breast cancerEvaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.Overdiagnosis of prostate cancer.Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in pIMPORTANCE OF PROSTATIC SPECIFIC ANTIGEN (PSA) IN CLINICAL PRACTICE : OUR EXPERIENCE.The effect of colonoscopy on serum prostate specific antigen levels.Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis.Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.Effect of ejaculation on serum prostate specific antigen level in screening and non-screening population.Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate.Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates.Immunophenotypic Characterization of Benign and Malignant Prostatic LesionsProstate specific antigen in urinary tract infection.cPSA and fPSA elimination in African-American men.The Correlation between Body Mass Index and Routine Parameters in Men Over Fifty.Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.Analysis of the early postoperative serum carcinoembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma.Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.
P2860
Q24632629-C7F17117-DB63-4EF5-8029-BA05C62BDB18Q24797983-ED8F9D56-E55C-42F2-A02E-41E35B6994C9Q26828563-D227F7DE-D296-44F7-8701-38EE587B898EQ26862434-4640A2CA-648D-48BE-A290-3A5E8078A418Q33711641-1CD7ECD3-B165-4082-B82D-1F30931FE88CQ33766462-7607F218-479B-4715-BBAF-EE279FD029DAQ34293280-3ACEB5BC-D736-43EF-B8C0-66483A14A39AQ35220192-740A379B-8E9E-460F-BA56-CB1457A470BCQ35847642-E2945682-2325-4AA6-BBDB-4E065C4E59E6Q35914400-3AEE18A5-7414-434A-969F-09A2F1BE93B7Q36081111-8FAFA71F-BF62-4404-B452-E0D9B787FCA9Q36173646-BC77F602-3772-48AB-A24D-8379EA9066C1Q36520508-4F255339-7305-4C65-9EF4-377DDA3BD571Q37379219-842FFF90-96F6-475C-900A-4EDB28D378A2Q41153935-C96F5097-5AFE-4963-B34D-40275558670CQ41687888-8F38A627-4007-45AB-9E3E-81CE5BF1B7AEQ41862818-EAE98B42-7CD7-4B37-80C5-3E4A8219E6B8Q41883096-8E24E8B9-53CD-4B51-B466-B4428AAF1C56Q41883300-BC976D25-07F1-4DB1-8AD1-3CD551DC6CF2Q41976110-F95C7BF6-2581-4C3D-AEA0-E77669F1CDE9Q42135518-252B2921-0C39-466F-BE9A-5FB8FF68D893Q42496163-CDCBC7F5-5BA7-4379-86FB-F05112A611EFQ43247951-1399432A-DB6A-46F2-8788-A52FA5A39A6EQ46270956-30E4940C-80C2-4353-A740-157778B14062Q47156572-80C6A124-71C7-4732-B659-2D39DBAEB666Q48215004-C8ABA999-C000-4E20-8F99-2C3FC8398589Q52054063-5385D463-18D4-4159-A706-87C6AD9B0C75Q52267080-BC05DC6D-9F4B-45AF-9C08-F7B11EFBDCFCQ54559731-37B71CB1-F8EB-4C73-850A-A9B190A86ED9
P2860
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Prostate specific antigen in t ...... ed with radical prostatectomy.
@en
Prostate specific antigen in t ...... ed with radical prostatectomy.
@nl
type
label
Prostate specific antigen in t ...... ed with radical prostatectomy.
@en
Prostate specific antigen in t ...... ed with radical prostatectomy.
@nl
prefLabel
Prostate specific antigen in t ...... ed with radical prostatectomy.
@en
Prostate specific antigen in t ...... ed with radical prostatectomy.
@nl
P2093
P1476
Prostate specific antigen in t ...... ed with radical prostatectomy.
@en
P2093
A W Kimball
C B Brendler
D J Bruzek
J E Oesterling
J I Epstein
P304
P356
10.1016/S0022-5347(17)42630-9
P407
P577
1988-04-01T00:00:00Z